Mar. 3 at 3:27 PM
$TMO is one of the largest global players in life sciences tools, diagnostics, and laboratory infrastructure. Market cap ~
$220B. 2024 revenue ~
$42.9B. It supplies platforms, reagents, and IVD systems used by major pharma and diagnostic labs worldwide. When a company of that scale signs a collaboration agreement, it signals technical alignment
The partnership centers on development and potential U.S. commercialization of a next-generation CRC test. Thermo provides PCR platforms and laboratory infrastructure;
$MYNZ contributes biomarker and mRNA assay expertise. For a microcap with an ~
$8M valuation, access to an established U.S. lab ecosystem is strategically meaningful
That said, financial terms, milestones, and exclusivity details are not publicly disclosed. A collaboration is not a guarantee of revenue scale or M&A. But structurally, it places a small-cap diagnostic developer inside the orbit of a
$220B industry heavyweight - a classic scale contrast worth noting
